ACP-5862 is a novel pyrrolidine ring-opened, major, active, and circulating metabolite of Acalabrutinib with an IC50 of 5.0 nM for Bruton tyrosine kinase (BTK). ACP�?862 is a weak time‐dependent inactivator of CYP3A4 and CYP2C8. Acalabrutinib is an orally bioavailable, irreversible, and highly specific BTK inhibitor, with an IC50 of 3 nM and EC50 of 8 nM.

纯度：≥98%

CAS�?230757-47-6